Compare Johnson & Johnson (JNJ) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Wells Fargo & Co — how do they compare? Johnson & Johnson trades at $261.35 (market cap $618.09B), while Wells Fargo & Co trades at $83.63 (market cap $248.06B). The key difference: Johnson & Johnson is far larger — about 2.5× Wells Fargo & Co's market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Wells Fargo & Co for 87 Days on average.
| JNJ | WFC | |
|---|---|---|
Market Cap | $618.09B | $248.06B |
Volume | 6,050,983 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $278.43 | $96.40 |
52-Week Low | $186.00 | $73.42 |
Typical Hold Time | 129 Days | 87 Days |
Enterprise Value | $646.37B | $503.91B |
Dividend Yield | 2.09% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Wells Fargo (WFC) trades at $83.16, up 3.61% today, showing resilience amid a bearish technical signal. The stock benefits from strong profitability with a 25.97% net margin and a modest P/E of 11.92, indicating potential undervaluation relative to earnings. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is cautiously optimistic, supported by analyst consensus targets near $99.13 and improving net interest income prospects from Fed rate hikes. Key risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and execution challenges amid leadership transitions like the chief risk officer's retirement (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
